Genomics pioneer J. Craig Venter has launched Diploid Genomics, Inc. (DGI), a new AI-driven genomics analytics company aimed at transforming disease discovery, diagnostics, and precision medicine.
The company is headquartered in La Jolla, California, and has been formed in partnership with Healthier Capital, which joins as a co-founder and the sole external investor in DGI’s seed funding round, closed in January 2026.
DGI is developing a next-generation genomics discovery and diagnostics platform focused on complex and life-threatening diseases. The company plans to integrate advanced artificial intelligence models with cutting-edge genomic sequencing, multimodal imaging, and longitudinal health data to deliver more precise and clinically actionable insights for life sciences companies, healthcare systems, researchers, and patients.
Designed as a high-leverage platform from inception, DGI is launching with access to extensive data and infrastructure assets. These include advanced sequencing technologies from Pacific Biosciences (PacBio) and Oxford Nanopore, specialized computing infrastructure, and proprietary genomics and imaging datasets from the J. Craig Venter Institute (JCVI), along with select collaborators. The company is also pursuing strategic partnerships with leading academic medical centers, AI organizations, and global life sciences companies.
DGI is establishing its own sequencing center at a new San Diego waterfront location and plans to seek Clinical Laboratory Improvement Amendments (CLIA) certification, enabling the delivery of AI-enhanced, next-generation clinical-grade sequencing services directly applicable to patient care.
The company is led by Dr. J. Craig Venter, alongside Anders Dale, Ph.D., a leader in multimodal imaging and data integration, and Eugene “Gene” Myers, Ph.D., a renowned computational scientist and bioinformatics pioneer. DGI has been formed using scientific expertise and intellectual foundations developed at JCVI, which is also an initial equity holder alongside DGI’s founders.
Dr. Venter is widely known for decoding the genome of the first free-living organism, founding Celera Genomics, which played a central role in sequencing the first human genome, and establishing multiple biotechnology companies including Synthetic Genomics, SGI-DNA, and Human Longevity, Inc. Dr. Dale brings decades of experience in quantitative imaging, neuroscience, and AI-driven health prediction, while Dr. Myers is recognized for developing foundational tools in genomics, including BLAST, and for leading large-scale genome assembly efforts.
Healthier Capital’s participation as co-founder reflects its strategic focus on AI-enabled healthcare platforms and translational science. Legal counsel to DGI was provided by Gibson, Dunn & Crutcher LLP.
With its combination of AI, genomics, imaging, and deep scientific leadership, Diploid Genomics aims to accelerate the shift toward more predictive, measurable, and actionable healthcare driven by human genomics.
